Page last updated: 2024-11-07

n,n'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127547
CHEMBL ID50262
SCHEMBL ID607073
MeSH IDM0104473

Synonyms (23)

Synonym
ditiomustine [inn]
1,1'-(dithiodiethylene)bis(3-(2-chloroethyl))-1-nitrosourea.
unii-810o95170j
810o95170j ,
1,1'-(dithiodiethylene)bis(3-(2-chloroethyl)-1(or 3)-nitrosourea
i.c.i.g. 1325
n,n'-bis((2-chloroethyl)-n-nitrosocarbamoyl)cystamine
di((chloro-2-ethyl)-2-n-nitroso-n-carbamoyl)-n,n-cystamine
n,n'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine
urea, 1,1'-dithiodiethylenebis(3-(2-chloroethyl)-3-nitroso-
brn 5158294
5,6-dithia-2,9,11-triazatridecanamide, 13-chloro-n-(2-chloroethyl)-n,11-dinitroso-10-oxo-
1,1'-dithiodiethylenebis(3-(2-chloroethyl)-3-nitrosourea)
ditiomustine
CHEMBL50262
82599-22-2
1-(2-chloroethyl)-3-[2-[2-[[2-chloroethyl(nitroso)carbamoyl]amino]ethyldisulfanyl]ethyl]-1-nitrosourea
77469-44-4
SCHEMBL607073
n,n'-bis[n-(2-chloroethyl)-n-nitrosocarbamoyl] cystamine
Q27269186
1,1'-(dithiodiethylene)bis(3-(2-chloroethyl))-1-nitrosourea
DTXSID80868665

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In the spleen both drugs provoked a higher toxic effect than in the bone marrow; on Day 1 they decreased the GM-CFUc population by 1 to 2 log."( In vivo acute hematotoxicity of N,N'-bis[N-(2-chloroethyl)-N-nitrosocarbamoyl]cystamine (CNCC), a new nitrosourea analog.
Blazsek, I; Jasmin, C; Maral, R; Mathé, G, 1984
)
0.27

Dosage Studied

ExcerptRelevanceReference
" These data highlight a novel role for cholesterol biosynthesis in cNCC physiology and demonstrate that human phenotypic variability in SMCHD1 mutation carriers may be related, in part, to SMCHD1's sensitivity to glucose or cholesterol dosage during development."( Cholesterol biosynthesis modulates differentiation in murine cranial neural crest cells.
Brooks, A; Fessler, MB; Icyuz, M; Karmaus, P; Pascual, F; Shaw, ND; Van Gorder, E, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID120840Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 20 mg/kg (i.p.)1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120849Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 30 mg/kg (i.p.); Toxic1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120848Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 30 mg/kg (i.p.); High percent value1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120844Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 2 mg/kg (i.p.)1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120841Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 20 mg/kg (i.p.); High percent value1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID120855Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 90 mg/kg (i.p.); Toxic1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120852Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 60 mg/kg (i.p.); High percent value1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120845Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 2 mg/kg (i.p.); Not significant1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120838Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 10 mg/kg (i.p.)1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120851Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 5 mg/kg (i.p.)1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID116715Acute LD50 of compound was evaluated on L1210 leukemia in mice1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID120839Compound was tested for its antitumor activity on L1210 leukemia in mice at the dose of 10 mg/kg (i.p.); High percent value1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
AID116716Acute LD50 of compound was evaluated on L1210 leukemia in mice when administered intraperitoneally1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Activated N-nitrosocarbamates for regioselective synthesis of N-nitrosoureas.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (40.91)18.7374
1990's0 (0.00)18.2507
2000's1 (4.55)29.6817
2010's0 (0.00)24.3611
2020's12 (54.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.88 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (92.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]